Cargando…

Survival Time in Treatment Modalities of Gastric Carcinoma at King Khalid Hospital- Jeddah Saudi Arabia: a Retrospective Cohort Study

BACKGROUND: Gastric cancer (GC) is the fifth most common cancer worldwide and is responsible for 10% of annual cancer deaths. Gastric cancer treatment requires a multimodality approach involving surgery, adjuvant chemotherapy (AC), and neoadjuvant chemotherapy (NAC) for locally advanced tumors. Surg...

Descripción completa

Detalles Bibliográficos
Autores principales: Alshahrani, Saad, Baabbad, Faisal, Bahobail, Majed, Hawsawi, Alaa, Jastania, Essam, Bamousa, Saeed, Shobair, Ammar, Zaidi, Syed Faisal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AVICENA, d.o.o., Sarajevo 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7879444/
https://www.ncbi.nlm.nih.gov/pubmed/33628129
http://dx.doi.org/10.5455/msm.2020.32.271-276
_version_ 1783650518442180608
author Alshahrani, Saad
Baabbad, Faisal
Bahobail, Majed
Hawsawi, Alaa
Jastania, Essam
Bamousa, Saeed
Shobair, Ammar
Zaidi, Syed Faisal
author_facet Alshahrani, Saad
Baabbad, Faisal
Bahobail, Majed
Hawsawi, Alaa
Jastania, Essam
Bamousa, Saeed
Shobair, Ammar
Zaidi, Syed Faisal
author_sort Alshahrani, Saad
collection PubMed
description BACKGROUND: Gastric cancer (GC) is the fifth most common cancer worldwide and is responsible for 10% of annual cancer deaths. Gastric cancer treatment requires a multimodality approach involving surgery, adjuvant chemotherapy (AC), and neoadjuvant chemotherapy (NAC) for locally advanced tumors. Surgical removal of the tumor is the most common and effective curative approach with a more promising survival rate. OBJECTIVES: Due to the scarcity of studies in the kingdom of Saudi Arabia, this study aims to provide an epidemiological background on the subject and compare multiple treatments and their survival outcomes in a tertiary hospital in the western region. METHODS: After obtaining the IB approval, data was collected from medical files of all histologically confirmed GC patients (101) between the years 2000-2015. In this study, patients’ demographics, tumor characteristics, treatment types, and patients’ vital status (deceased or alive) were collected. Survival analysis between treatment modalities subgroups was carried out using the Kaplan-Meier test and Cox regression model. RESULTS: Out of 101 patients with GC, 65.35% were males with a mean age of 64.9±19 years and 61.71±17.83 years for female patients. Most patients had a stage IV tumor 47 (74.6%). The adjuvant chemotherapy group had a median survival time of 140 months (95% CI 33.72-246.29), while the neoadjuvant chemotherapy was 69 months. Patients who only underwent surgery had a median survival time of 28 months (95% CI 0-56.14), whereas patients who received no intervention had a median survival time of 8 months (95% CI 1.47-14.53) (log-rank = 0.002). The median overall survival time for all patients was 28 months (95%CI 0-77.68) with an overall five-year survival rate of 19.6%. Cox regression model revealed that treatment type and tumor stage were significant predictors of survival with p values of 0.001 and 0.009, respectively. CONCLUSION: Adjuvant, neoadjuvant, and palliative chemotherapy constitute the paramount treatment modalities of GC with adjuvant treatment having the highest survival time. However, these modalities necessitate further understanding as to whether other factors play a role in the selection of one treatment with the preferable outcome.
format Online
Article
Text
id pubmed-7879444
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher AVICENA, d.o.o., Sarajevo
record_format MEDLINE/PubMed
spelling pubmed-78794442021-02-23 Survival Time in Treatment Modalities of Gastric Carcinoma at King Khalid Hospital- Jeddah Saudi Arabia: a Retrospective Cohort Study Alshahrani, Saad Baabbad, Faisal Bahobail, Majed Hawsawi, Alaa Jastania, Essam Bamousa, Saeed Shobair, Ammar Zaidi, Syed Faisal Mater Sociomed Original Paper BACKGROUND: Gastric cancer (GC) is the fifth most common cancer worldwide and is responsible for 10% of annual cancer deaths. Gastric cancer treatment requires a multimodality approach involving surgery, adjuvant chemotherapy (AC), and neoadjuvant chemotherapy (NAC) for locally advanced tumors. Surgical removal of the tumor is the most common and effective curative approach with a more promising survival rate. OBJECTIVES: Due to the scarcity of studies in the kingdom of Saudi Arabia, this study aims to provide an epidemiological background on the subject and compare multiple treatments and their survival outcomes in a tertiary hospital in the western region. METHODS: After obtaining the IB approval, data was collected from medical files of all histologically confirmed GC patients (101) between the years 2000-2015. In this study, patients’ demographics, tumor characteristics, treatment types, and patients’ vital status (deceased or alive) were collected. Survival analysis between treatment modalities subgroups was carried out using the Kaplan-Meier test and Cox regression model. RESULTS: Out of 101 patients with GC, 65.35% were males with a mean age of 64.9±19 years and 61.71±17.83 years for female patients. Most patients had a stage IV tumor 47 (74.6%). The adjuvant chemotherapy group had a median survival time of 140 months (95% CI 33.72-246.29), while the neoadjuvant chemotherapy was 69 months. Patients who only underwent surgery had a median survival time of 28 months (95% CI 0-56.14), whereas patients who received no intervention had a median survival time of 8 months (95% CI 1.47-14.53) (log-rank = 0.002). The median overall survival time for all patients was 28 months (95%CI 0-77.68) with an overall five-year survival rate of 19.6%. Cox regression model revealed that treatment type and tumor stage were significant predictors of survival with p values of 0.001 and 0.009, respectively. CONCLUSION: Adjuvant, neoadjuvant, and palliative chemotherapy constitute the paramount treatment modalities of GC with adjuvant treatment having the highest survival time. However, these modalities necessitate further understanding as to whether other factors play a role in the selection of one treatment with the preferable outcome. AVICENA, d.o.o., Sarajevo 2020-12 /pmc/articles/PMC7879444/ /pubmed/33628129 http://dx.doi.org/10.5455/msm.2020.32.271-276 Text en © 2020 Saad Alshahrani, Faisal Baabbad, Majed Bahobail, Alaa Hawsawi, Essam Jastania, Saeed Bamousa, Ammar Shobair, Syed Faisal Zaidi http://creativecommons.org/licenses/by-nc/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Paper
Alshahrani, Saad
Baabbad, Faisal
Bahobail, Majed
Hawsawi, Alaa
Jastania, Essam
Bamousa, Saeed
Shobair, Ammar
Zaidi, Syed Faisal
Survival Time in Treatment Modalities of Gastric Carcinoma at King Khalid Hospital- Jeddah Saudi Arabia: a Retrospective Cohort Study
title Survival Time in Treatment Modalities of Gastric Carcinoma at King Khalid Hospital- Jeddah Saudi Arabia: a Retrospective Cohort Study
title_full Survival Time in Treatment Modalities of Gastric Carcinoma at King Khalid Hospital- Jeddah Saudi Arabia: a Retrospective Cohort Study
title_fullStr Survival Time in Treatment Modalities of Gastric Carcinoma at King Khalid Hospital- Jeddah Saudi Arabia: a Retrospective Cohort Study
title_full_unstemmed Survival Time in Treatment Modalities of Gastric Carcinoma at King Khalid Hospital- Jeddah Saudi Arabia: a Retrospective Cohort Study
title_short Survival Time in Treatment Modalities of Gastric Carcinoma at King Khalid Hospital- Jeddah Saudi Arabia: a Retrospective Cohort Study
title_sort survival time in treatment modalities of gastric carcinoma at king khalid hospital- jeddah saudi arabia: a retrospective cohort study
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7879444/
https://www.ncbi.nlm.nih.gov/pubmed/33628129
http://dx.doi.org/10.5455/msm.2020.32.271-276
work_keys_str_mv AT alshahranisaad survivaltimeintreatmentmodalitiesofgastriccarcinomaatkingkhalidhospitaljeddahsaudiarabiaaretrospectivecohortstudy
AT baabbadfaisal survivaltimeintreatmentmodalitiesofgastriccarcinomaatkingkhalidhospitaljeddahsaudiarabiaaretrospectivecohortstudy
AT bahobailmajed survivaltimeintreatmentmodalitiesofgastriccarcinomaatkingkhalidhospitaljeddahsaudiarabiaaretrospectivecohortstudy
AT hawsawialaa survivaltimeintreatmentmodalitiesofgastriccarcinomaatkingkhalidhospitaljeddahsaudiarabiaaretrospectivecohortstudy
AT jastaniaessam survivaltimeintreatmentmodalitiesofgastriccarcinomaatkingkhalidhospitaljeddahsaudiarabiaaretrospectivecohortstudy
AT bamousasaeed survivaltimeintreatmentmodalitiesofgastriccarcinomaatkingkhalidhospitaljeddahsaudiarabiaaretrospectivecohortstudy
AT shobairammar survivaltimeintreatmentmodalitiesofgastriccarcinomaatkingkhalidhospitaljeddahsaudiarabiaaretrospectivecohortstudy
AT zaidisyedfaisal survivaltimeintreatmentmodalitiesofgastriccarcinomaatkingkhalidhospitaljeddahsaudiarabiaaretrospectivecohortstudy